Novartis adult migraine erenumab injection approved by the National Drug Administration

Recently, the(http://of Novartis (China) Biomedical ResearchCompany was granted an adaffle by the State Drug Administration's ClinicalTrial(http://)the erenumab injection for the prevention of migraines in adultsErenumab, the first preventive migraine treatment approved by theFDA(http://,drug(http://, was jointly developed by Novartis and Amgen and was approved in the U.Slast May to play a role in blocking the activity of calcitonin gene-related peptides (CGRP), a molecule involved in migraine attacks 　　Erenumab has been selected as the 2018 drug-watching "2018 Drug Prediction" produced by Coreveh, which is expected to be a heavyweight new drug (http:// with sales of $1 billion or more in 2022 　　Erenumab has been tested in several large,scale global, randomized, double-blind, placebo-controlled studies involving more than 2,600 patients in clinical programs to assess the drug's safety and efficacy in migraine prevention 　　In a multicenter called LIBERTY, a randomized double-blind clinical phase 3b trial with placebo control, 246 patients with seizure migraines were randomly treated with erenumab or placebo for a monthly subcutaneous injection In the 9-12 weeks after the clinical trial began, 30.3% of patients treated with erenumab had a reduction of at least 50% of the number of migraine attack days, a significantly higher number than the control group (13.7%, p0.002, with an advantage ratio of 2.73 ) All secondary endpoints include changes in the number of days of migraines per month, changes in the number of days of treatment for acute migraines per month, changes in migraine body function impact log (MPFID) scores, and the proportion of patients who achieved 75% and 100% remission rates (at least 75 or 100% less than placebos)